Molecule to Market: Inside the outsourcing space

• The bullish CDMO CEO making bold moves

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeremie Trochu, CEO at Ardena. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeremie, covering: The value of hitting the road and getting in front of clients, helping build several career-critical skills The big decision to leave med-tech giant GE and move to an ambitious, growing CDMO called...Catalent How the stars aligned to move back to Europe and join Ardena as CEO...and the secret sauce behind its suite of integrated development capabilities A transformational acquisition of Catalent's Somerset, NJ facility to help take Ardena to the next level as a global CDMO The importance of remembering that we are part of a cyclical industry and must ride out the lows, but we must remain adaptive and bullish about the market's growth Why VUCA (volatility, uncertainty, complexity, ambiguity) is inevitable Jeremie joined Ardena as Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry and a proven track record of success in the biopharma sector. He has 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in publicly traded and privately held companies.  Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO. During his tenure there, he led multiple companies' successful acquisitions and integrations. He holds a master's degree in Business Administration from EMLyon, France. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  50:39
• Geordie lad done good in pharma

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rob Wood, pharma portfolio investor and Founder. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob, covering: Identifying a niche in the pharma services space that led to working with top 50 Big Pharma Growing STEM into an international powerhouse before eventually selling to UDG Healthcare Life as a pharma portfolio advisor and investor of seven pharma services companies Creating an academy that will introduce entrepreneurship to hundreds of thousands of kids How AI will impact the commercialization of new and existing drugs Rob Wood is an experienced entrepreneur in the pharma services industry. He founded, scaled, and sold STEM for €120 million, expanding into 51 countries and working with all of the top 50 pharmaceutical companies. STEM grew to over 1,000 staff globally and received the Queen's Award for International Trade. After selling STEM, Rob joined UDG plc as CEO & President of Advisory and Head of Group Business Development, leading multiple healthcare consultancies and re-modelling business development across 28 companies. Today, Rob serves as Chairman or Non-Executive Director for several healthcare service companies, focusing on growth, leadership, and investment opportunities. He holds an MBA from Newcastle University. He recently founded the Rob Wood Enterprising Futures Academy in conjunction with Newcastle University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  56:40
• The CEO driven by lentiviral vector success

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jon Alberdi, CEO at VIVEbiotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering: Falling in love with the world of management and its role in influencing people and society Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space? His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize The before and after of a PE deal with Ampersand - speed, challenge, and intensity Riding the growth of CAR-T products, and which therapy areas are driving demand Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN, where he held several financial controlling roles, including the R&D department at the worldwide product development centre. He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

  --------  

  48:58
• The CRDMO CEO making his luck

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Philip Lee, CEO at GeneFab. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Philip, covering: The role of luck in the development of his entrepreneurial journey of multiple biopharma start-ups Bootstrapping a biological tech company and then selling to Millipore, along with lessons learnt from a more prominent global organization Building a new company from the back of a napkin to an IPO on the NASDAQ Creating a technology platform and operational capability with real therapeutic application that led to the spin-out of Genefab Bridging the gap for early-stage cell therapy companies with aligned incentives and a non-transactional model Philip Lee is a bioengineer, biotechnology entrepreneur, and executive who has spent the last 20 years building companies and commercializing products, including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and advanced manufacturing services. He has been the “first employee” at multiple ventures with leadership experience across diverse growth trajectories, including bootstrapping, VC and PE funding rounds, IPO, acquisition, and internal innovation within a large enterprise. Philip holds degrees from the Massachusetts Institute of Technology and the UC Berkeley/UCSF Joint Graduate Program in Bioengineering. Philip is currently the founding CEO of GeneFab, a contract research, development, and manufacturing organization focused on supporting its clients in bringing innovative genetic medicines to needy patients.  Before GeneFab, Philip was the Co-Founder and CTO of Senti Biosciences, a cell and gene therapy company applying gene circuit technology to improve the efficacy and safety of cancer cell therapies. Philip was also the co-founder and CEO of Cellasic Corp, a microfluidics instrumentation company that MilliporeSigma had acquired. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  50:28
• The biotech CEO focused on curing paediatric deafness

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jodi Cook PhD, President and CEO at Skylark Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering: How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients? Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark. Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics, overseeing its $1 billion acquisition. She earned her Ph.D. from Arizona State University, a Master’s in Audiology from the University of South Carolina, and a Bachelor of Arts from Loyola University Maryland. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals and was previously Board Chair of STRM.BIO. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

  --------  

  52:59

Más podcasts de Ciencias

Podcasts a la moda de Ciencias

Acerca de Molecule to Market: Inside the outsourcing space